Cancer & Infectious disease vaccines, contract services

Medigen, Inc. is at the forefront of developing innovative vaccines aimed at providing long-lasting immunity against a range of emerging diseases. The company focuses on creating vaccines that mimic natural viruses while ensuring safety and inducing robust immune responses. Their research encompasses various viral threats, including Chikungunya, Venezuelan equine encephalitis, and other significant pathogens such as those causing influenza and Zika. Medigen's commitment to vaccine safety and efficacy is evident in their approach to vaccine design, which emphasizes natural immunity and the use of advanced technologies.

One of the key technologies employed by Medigen is their patented DNA-launched iDNA vaccine platform, which combines the genetic stability of DNA with the effectiveness of live attenuated vaccines. This innovative method allows for the development of vaccines that can be administered directly to patients or produced in cell cultures. The iDNA technology not only enhances safety due to its genetic stability but also offers logistical advantages, such as the potential to eliminate the need for cold chain storage. Medigen's expertise in Virus-Like Particle (VLP) production further supports their vaccine development efforts, enabling the creation of custom VLPs for various viruses, thereby enhancing their ability to respond to public health challenges effectively.

United States

Biopharmaceutical Company engaged in vaccine development against emerging viruses and biopharma CDMO manufacturing.

MEDIGEN, INC.

Company Details